Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Buying Wonderful Businesses At Fair Prices - The Billionaire Way
07:30am, Monday, 19'th Aug 2024
Warren Buffett's success stems from evolving his strategy to focus on buying high-quality businesses at fair prices rather than just seeking deep-value investments. By deeply understanding businesses
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
03:19am, Sunday, 18'th Aug 2024
Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
09:06am, Thursday, 15'th Aug 2024
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
07:00am, Thursday, 15'th Aug 2024
The Dow Jones has edged higher this year despite concerns about a possible recession. This dynamic favors stocks with a defensive tilt.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
06:15am, Wednesday, 14'th Aug 2024
The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others.
Merck: Buy This Bargain Before It's Gone
05:54pm, Monday, 12'th Aug 2024
Despite Merck beating analysts' expectations for the second quarter of 2024, its stock price fell 9%. The company's stock sell-off came as a result of an unexpected decline in sales of the Gardasil fr
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
12:20pm, Monday, 12'th Aug 2024
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Buy 10 Sustainable Dividend Dogs Of Barron's August 100
10:02am, Sunday, 11'th Aug 2024
Barron's seventh annual (2024) ranking of Sustainable companies started with the 1,000 largest publicly traded companies by market value, then ranked each by performance for five key constituencies: s
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
03:18pm, Friday, 09'th Aug 2024
On Friday, Merck & Co Inc MRK agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billion
07:54am, Friday, 09'th Aug 2024
Merck said Friday it's has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:06am, Thursday, 08'th Aug 2024
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck says it's discontinuing a late-stage trial of a lung cancer treatment after high number of adverse events
07:09am, Thursday, 08'th Aug 2024
Merck & Co. MRK, +1.21% said Thursday it's discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse ev
Merck stops experimental lung cancer drug combo trial
06:58am, Thursday, 08'th Aug 2024
Merck said on Thursday it had discontinued its trial of a combination of its experimental drug and blockbuster therapy Keytruda for the treatment of a type of lung cancer, after an interim analysis sh
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Update on Phase 3 KeyVibe-008 Trial Evaluating Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With ES-SCLC.
The 3 Best Biotech Stocks to Buy in August 2024
06:30am, Thursday, 08'th Aug 2024
Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.
